Revvity Inc. (RVTY) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup skews to beat on the underlying business, but the bar is nuanced — consensus is modeling only ~2% pro forma organic growth for Q2 vs. management's guided 2–3% range, and the bigger swing factor is whether the software segment's guided ~20% decline proves conservative or accurate given tough year-ago comps.

Heading into Q2 2026, the bar for Revvity is manageable: consensus sits at ~$702M in pro forma revenue and ~$1.23 in adjusted EPS, both roughly in line with management's guided ranges ($699M–$707M revenue; ~23% of full-year EPS, implying ~$1.21–$1.24). Management's posture since the Q1 print has been incrementally more confident — the Eurobond was repaid in mid-July, freeing capital for buybacks, and multiple conference appearances (June 9 Jefferies) reinforced conviction in the pro forma organic growth framework. Estimate revisions have been essentially flat since the Q1 print, with the as-of 5/12/26 consensus nearly identical to current, suggesting the Street has largely digested the China ID divestiture and is not pricing in incremental upside. The stock has rallied ~25% since Q1 earnings (vs. XBI +10%, SPY +5%), meaning some beat is already priced in and the reaction function is asymmetric — a clean beat on diagnostics and reagents with software in-line could be muted, while any miss on the software trajectory or pharma/biotech demand would be punished. The key wildcard is software: guided down ~20% in Q2 due to tough comps before re-accelerating to high-teens in H2 — if the decline is shallower than feared (e.g., early Biodesign traction or Synthetica pull-through), that alone could drive a meaningful upside surprise on both revenue and margin.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar on revenue (~$702M vs. guided $699–$707M) and EPS (~$1.23 vs. implied ~$1.21–$1.24), with organic revenue growth the bigger swing factor — consensus at ~1.8% sits below the guided 2–3% range, leaving room for a beat if diagnostics and reagents hold up.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha consensus and actuals data; Q2 2026 guidance from Q1 2026 earnings call (May 5, 2026). Pro forma figures exclude China Immunodiagnostics business. Q1 2026 Actual = last reported quarter. Q2 2025 Actual = prior year comparable period.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top KPI 1: Pro Forma Revenue (Operating) | Top KPI 2: Adjusted Diluted EPS (Operating)

Pattern: RVTY has consistently beaten on EPS (4 of 4 recent quarters with data) while missing on reported revenue — a pattern driven by the China ID business drag and conservative cost management. The EPS beat cadence is durable; the revenue miss pattern is largely a pro forma vs. reported definitional issue post-divestiture announcement. Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been formally reset post-Q1 to a pro forma framework (excluding China ID), with no post-earnings revisions to Q2 or FY2026 guidance since the May 5 print. Management tone at the June 9 Jefferies conference was incrementally more confident on pharma/biotech recovery and software pipeline, while maintaining prudent assumptions.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q1 print — the Street has absorbed the China ID divestiture and is tracking guidance closely. The lack of upward revision despite improving pharma/biotech signals is a potential source of cushion heading into Q2, particularly on EPS where the beat cadence has been consistent.

Estimates have been remarkably stable since the Q1 print, with essentially zero revision on EPS and less than 0.5% movement on revenue. The Street is tracking guidance closely but sitting slightly below the midpoint on organic growth — a setup that creates a low bar for a beat if pharma/biotech demand continues to improve. Source: Visible Alpha consensus and actuals data.

5. Stock Performance

Key Takeaway: RVTY has significantly outperformed since Q1 earnings (+24.8% vs. XBI +10.1%, SPY +4.7%), driven by multiple re-rating on the cleaner pro forma story and improving pharma/biotech sentiment — the stock's outperformance is sentiment- and multiple-driven rather than estimate-driven, creating an asymmetric reaction function into Q2.

RVTY vs. XBI (Biotech ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (May 5, 2026). Source: Stock Price Data.

• RVTY +24.8% since Q1 earnings (May 5 – Aug 4, 2026), vs. XBI +10.1% and SPY +4.7%. Significant outperformance driven by multiple re-rating on the pro forma story.
• Key inflection point: June 24–25, 2026 — RVTY surged ~7.5% in two sessions coinciding with the Eurobond repayment completion and a broader biotech sector rally (XBI also rallied ~3% in the same window). This marked the stock's breakout above $105.
• Post-breakout consolidation: Stock has traded in the $108–$115 range since late June, suggesting the market is waiting for Q2 results to validate the pro forma growth thesis before extending the multiple further.
• Sector ETF used: XBI (SPDR S&P Biotech ETF) — selected as the most relevant sub-sector benchmark given RVTY's life sciences tools and diagnostics exposure and its correlation to biotech funding/spending cycles.
• Analyst consensus: Hold (2 Sell, 10 Hold, 4 Buy); average price target ~$108.92 (slight downside from current ~$115). Evercore reiterated Outperform with $125 PT on July 6; TD Cowen reiterated Buy on July 15; Bernstein initiated Market Perform at $115 on June 26; Wolfe initiated Peer Perform on June 2.

6. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peer Q2 2026 earnings and conference commentary paint a broadly constructive picture for RVTY's Q2 setup — pharma/biotech demand is recovering across the board (TMO, DHR, MTD all confirmed), academic/government is stabilizing, and diagnostics ex-China is strong. The main risk is software, where RVTY has idiosyncratic tough comps that peers don’t share.

Note: Only commentary from peers' Q2 2026 earnings calls and post-Q1 2026 conferences (i.e., commentary about the current reporting quarter or the current environment) is included below. Prior-quarter earnings commentary has been excluded.

Danaher (DHR) — Q2 2026 Earnings (July 21, 2026)

Read-through: Positive for RVTY Life Sciences and Diagnostics.

• Pharma/biotech demand healthy and improving: DHR reported Life Sciences core revenue +5.5% in Q2, with large pharma/biopharma customers "progressing back to normal" and biotech demand benefiting from a more favorable funding environment. Funding is now "starting to play through" into orders and revenue — a direct positive read-through for RVTY's reagents and instruments businesses.
• Instruments growing mid-single digits: DHR's life sciences instrument businesses grew mid-single digits in Q2, with equipment growth in bioprocessing following several quarters of improving order trends. This validates RVTY's assumption of mid-single-digit instrument growth in Q2.
• Diagnostics ex-China strong: Clinical diagnostics businesses up mid-single digits with high-single-digit growth outside China. Declines in China began to moderate as pricing stabilized. Directly supportive of RVTY's guided mid-to-high single-digit diagnostics growth in Q2.
• Academic/government stabilizing but not inflecting: Academic demand improved modestly as the quarter progressed but remained below normal levels. DHR noted academia is less than 5% of revenues and they need to see a more constructive funding perspective before calling an inflection. Consistent with RVTY's prudent academic assumptions.
• Q3 2026 guidance: DHR guided Q3 revenue growth of ~2–3% with core growth ex-respiratory of ~5%, an acceleration from Q2. Full-year core revenue growth raised to 3–4%. Positive for RVTY's H2 acceleration thesis.

Thermo Fisher Scientific (TMO) — Q2 2026 Earnings (July 23, 2026)

Read-through: Strongly positive for RVTY pharma/biotech and reagents.

• "Clean top and bottom line beat" with 5% organic growth: TMO delivered 5% organic revenue growth and 13% adjusted EPS growth in Q2, "significantly ahead of prior guidance." This is the strongest signal yet that the pharma/biotech recovery is real and broad-based.
• Pharma/biotech mid-single-digit growth: TMO delivered mid-single-digit growth from pharma/biotech customers, led by bioproduction and clinical research. Management noted "real signs of the biotech recovery" with broad-based momentum and "very strong growth" in bioproduction. Directly positive for RVTY's reagents and instruments businesses.
• Academic/government returned to growth: TMO grew low single digits in academic/government in Q2, with the US slightly positive. Management noted the market is "going through a stabilization period" and did not change the outlook, but the return to growth is incrementally positive for RVTY.
• Full-year guidance raised: TMO raised full-year organic revenue growth to ~4% (upper end of 3–4% range) and raised adjusted EPS guidance to $24.93–$25.33 (+11% growth). This level of confidence from the largest life sciences tools company is a strong positive read-through for the sector.
• Large pharma excitement about pipelines: TMO management noted large pharma executives showing "a lot of excitement about their pipelines" and focusing on accelerating innovation — a positive leading indicator for RVTY's Signals software and reagents demand.

Mettler-Toledo (MTD) — Q2 2026 Earnings (July 31, 2026)

Read-through: Positive for RVTY biopharma and instruments; mixed on China.

• Biopharma demand healthy: MTD noted improving trends across the biopharma customer base with strong growth in process analytics and bioproduction laboratory balances and analytical instruments. Biopharma was a "good part of the industrial growth" in China as well.
• Lab business reaccelerating: MTD's lab business returned to growth with the pipetting business coming back in Q2. Management attributed this to innovation and strong go-to-market execution — consistent with RVTY's thesis that instrument demand is normalizing.
• Reshoring in early innings: MTD sees some reshoring-related RFQs but characterizes it as "early innings," with momentum expected to pick up in H2 2026 and into 2027–2028. Consistent with RVTY's GMP capacity buildout thesis (benefits expected in late 2027–2028).
• Full-year guidance raised: MTD raised local currency sales growth guidance to ~4–5% (from ~4%) and raised adjusted EPS guidance to $47.15–$47.50 (+10–11% growth). Positive sector read-through.
• China high-single-digit growth expected: MTD guided high-single-digit China growth for Q3 and full year. Note: RVTY has divested its China ID business, so China exposure is now primarily through Life Sciences, where trends are improving.

IQVIA Holdings (IQV) — Q2 2026 Earnings (July 28, 2026)

Read-through: Positive for RVTY's Signals software and drug discovery thesis.

• Biotech funding at $35B in Q2 — more than double Q2 2025: IQV reported Q2 2026 emerging biopharma funding of $35B (per Bioworld), more than double the Q2 2025 level. This is the strongest biotech funding environment in years and is a leading indicator for RVTY's reagents and software demand.
• AI driving demand for CRO services: Large pharma clients are telling IQV that AI in discovery will "only increase demand for CRO services" as more molecules with higher predictable success enter development. Some clients are predicting they will double their study portfolios. This directly validates RVTY's thesis that AI-generated discoveries require physical validation through consumables, instruments, and software.
• Phase III opportunities at 50% of total volume (vs. 40% a year ago): More assets moving into later-stage development is a positive leading indicator for RVTY's reagents and instruments demand as programs scale up.
• Full-year guidance raised: IQV raised full-year revenue guidance to $17.275B–$17.475B (+6.5% midpoint) and raised adjusted EPS to $12.80–$13.00. Strong CRO demand is a positive read-through for RVTY's pharma/biotech end market.
• New drug launches up ~45% in H1 2026 vs. H1 2025: This launch activity drives demand for RVTY's commercial-stage reagents and instruments as programs scale from development to manufacturing.

ICON plc (ICLR) — Q2 2026 Earnings (July 30, 2026)

Read-through: Positive for RVTY's pharma/biotech end market; biotech acceleration notable.

• Gross business wins +24% YoY, +13% sequentially: ICLR reported Q2 gross wins of $3.7B with a net book-to-bill of 1.51x. Biotech was a "marked increase" in the quarter, with mid-sized biotechs representing 8 of the top 10 customers by awards. This biotech acceleration is a positive read-through for RVTY's reagents and software demand.
• RFP flow +22% sequentially, +16% on trailing 12-month basis: Strong RFP flow indicates robust pipeline activity that will translate into reagent and instrument demand for RVTY over the next 6–12 months.
• Phase III at 50% of opportunity volume: Consistent with IQV's commentary — more assets in later-stage development is a positive leading indicator for RVTY's consumables demand.
• China revenue up ~20% full-year 2026: ICLR noted notable improvement in China demand over the last 12 months, with revenue potentially up 20% full-year. While RVTY has divested its China ID business, this signals improving China biotech activity that could benefit RVTY's Life Sciences segment.

Waters Corporation (WAT) — Jefferies Global Healthcare Conference (June 3, 2026)

Read-through: Positive for RVTY pharma instruments; China pharma a standout.

• Pharma mid-teens growth overall; China pharma +50%: WAT reported pharma as a "standout" with mid-teens growth overall and high-single-digit growth in the US and Europe. China pharma grew over 50%, driven by local biotech fueling CDMO and local pharma expansion. While RVTY's China exposure is now limited post-divestiture, this signals strong underlying pharma demand globally.
• Instruments high-single-digit growth; LC-MS replacement cycle "very strong": WAT's instruments grew high-single digits with the LC-MS replacement cycle described as very strong. This is consistent with RVTY's assumption of mid-single-digit instrument growth in Q2 and validates the broader instrument demand recovery thesis.
• Research reagents business "very good": WAT highlighted its research reagents business as a strong performer, with chemistry growing ~13% in Q1. Positive read-through for RVTY's Life Sciences Solutions reagents business.
• Derisking H2: WAT management noted they are "derisking" the second half and building in "even more prudence" — consistent with RVTY's conservative H2 assumptions and suggesting the sector is not over-promising on H2 recovery.

Agilent Technologies (A) — Jefferies Global Healthcare Conference (June 3, 2026)

Read-through: Positive for RVTY pharma and diagnostics; China soft but improving.

• Q2 2026 reported 6.3% growth, 14% EPS growth — well ahead of guidance: Agilent's strong Q2 beat (reported at the conference) is a positive read-through for the broader life sciences tools sector heading into RVTY's Q2 print.
• Pharma "in line, still really strong"; biotech low double-digit growth: Agilent reported pharma in line with expectations and biotech growing low double digits. Large-cap pharma "fine"; mid-cap still soft. Consistent with RVTY's low-single-digit pharma/biotech growth assumption for Q2.
• Diagnostics +11% in Q2: Agilent's diagnostics business grew 11% in Q2, driven by favorable demographics and strong technology traction. Positive read-through for RVTY's diagnostics segment guided at mid-to-high single digits.
• LC/LCMS low double-digit growth; replacement cycle 1/3 through: Agilent's instrument replacement cycle is well underway, with LC/LCMS growing low double digits. This validates RVTY's instrument recovery thesis and suggests the cycle has further to run.
• China soft (-9%) but expected to improve in 2027: Agilent's China was down 9% in Q2 due to Lunar New Year effects and tough comps. SAMR stimulus now expected in 2027 rather than 2026. Limited direct read-through for RVTY given the China ID divestiture.

Charles River Laboratories (CRL) — William Blair Growth Stock Conference (June 2, 2026)

Read-through: Positive for RVTY's drug discovery and preclinical demand thesis.

• Biotech net bookings at highest level in over 2 years: CRL reported biotech net bookings at their highest level in over 2 years, with mid-sized biotechs having better access to capital as they approach IND and enter the clinic. This is a direct positive read-through for RVTY's Signals software and preclinical reagents demand.
• Global biopharma clients "back to work": CRL noted that global biopharma clients have "progressed through the restructuring and pipeline activities and are back to work." This validates RVTY's Q1 observation that pharma/biotech delivered the strongest growth since H1 2023.
• AI as a structural tailwind for preclinical services: CRL views AI as a structural tailwind, with ~60% of R&D executives expecting AI investments to result in increased IND approvals and faster drug discovery. "More programs equals more opportunities entering Charles River's pipeline" — and by extension, more demand for RVTY's reagents, instruments, and software.
• DSA demand trends favorable; positioned for H2 organic revenue growth: CRL noted favorable DSA demand trends in Q1 leaving them well positioned to return to DSA organic revenue growth in H2 2026. Positive for RVTY's pharma/biotech end market outlook.

Summary Read-Through Table:

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Eurobond repayment completion in mid-July 2026, which removes the near-term capital constraint and opens the door for buybacks — a catalyst management explicitly flagged as the primary capital deployment preference given current valuation.

• August 4, 2026 — Q2 2026 Earnings Call scheduled. Revvity confirmed the earnings call date via press release on July 8, 2026. Key focus areas: pro forma organic growth vs. guided 2–3%, software trajectory (guided -20% in Q2 before H2 re-acceleration), margin progression toward 28.4% full-year target, and capital deployment update post-Eurobond repayment.
• May 5, 2026 — China Immunodiagnostics Divestiture Announced. Revvity announced the divestiture of its China Immunodiagnostics business (representing ~6% of prior-year revenue) to a local management-led group for up to $200M. Transaction expected to close by end of 2027. This was the dominant story of Q1 earnings, resetting the financial framework to a pro forma basis. Implication: Removes a persistent drag on organic growth (~100 bps improvement) and margins (~30 bps improvement), and eliminates a meaningful FCF headwind. The pro forma story is cleaner and higher-quality.
• Mid-July 2026 — Eurobond Repayment Completed. Management flagged the maturing Eurobond repayment as the near-term capital priority at Q1 earnings. Completion removes the constraint and enables the explicitly stated primary capital deployment preference: share buybacks. Implication: Expect buyback announcement or update on Q2 call; this is a potential positive catalyst for EPS.
• Q2 2026 — Biodesign Platform Launched. Revvity launched Biodesign, its cloud-native molecular design platform for biologics development, in Q2 2026. Early beta customer feedback was positive, though management noted it typically takes a few quarters before new product launches translate into contract traction. Implication: Revenue contribution more of a 2027 phenomenon, but launch validates the software innovation pipeline and supports the APV growth trajectory.
• June 9, 2026 — Jefferies Global Healthcare Conference. Management confirmed Synthetica (AI models as a service, in partnership with Lilly TuneLab) was launching imminently, bringing an ecosystem of over 200 biotech companies. Biodesign had positive early beta feedback. Management reiterated confidence in the pro forma organic growth framework and highlighted software APV continuing to grow double digits. Implication: Incrementally more confident tone vs. Q1 earnings; no guidance changes.
• June 26, 2026 — Bernstein Initiated Coverage at Market Perform, $115 PT. Sanford C. Bernstein initiated coverage with a Market Perform rating and $115 price target. Implication: Neutral initiation from a major firm; $115 PT is at the high end of the consensus range and suggests limited near-term upside at current levels.
• July 6, 2026 — Evercore Reiterated Outperform, $125 PT. Evercore restated its Outperform rating and $125 price target, the highest on the Street. Implication: Most bullish analyst sees ~10% upside from current levels; thesis likely centered on software re-acceleration and margin expansion.
• July 15, 2026 — TD Cowen Reiterated Buy. TD Cowen reaffirmed its Buy rating ahead of Q2 earnings. Implication: Constructive setup from a key bull; suggests the buy-side is not broadly positioned for a miss.
• November 13, 2026 — Investor Day Scheduled. Revvity has scheduled an Investor Day for November 13, 2026, where software strategy and long-range plan progress will be central themes. Implication: Creates a medium-term catalyst for multiple re-rating if management can demonstrate the software APV growth trajectory and margin expansion roadmap.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells from executives since Q1 earnings. The only insider sale was a small 10b5-1 planned sale by the CAO in July. The absence of discretionary selling by senior management is a mild positive signal heading into Q2 earnings.

Source: SEC Form 4 filings (Insider Transaction Data). Open-market buys (P-code) and discretionary sells (S-code) only: None filed since Q1 earnings. The only sell-side activity was a small 10b5-1 planned sale by the CAO (85 shares, July 20) and a routine tax withholding (33 shares, June 15). All other transactions are routine annual director equity awards (A-code). No clustered buys or unusual discretionary sales — nothing notable from an insider signal perspective.